Pentracor was awarded the "Zukunftspreis Brandenburg" 2021

12.11.2021
Pentracor was awarded the "Zukunftspreis Brandenburg" 2021!
A total of six companies and one special prize winner were awarded the state's most important business prize, the "Zukunftspreis Brandenburg" 2021. With their business ideas and developments, they convinced the top-class jury of 16 of their special achievements for the Brandenburg economy. Brandenburg's Minister President Dr. Dietmar Woidke congratulated the winners at the Holiday Inn Berlin Airport Conference Centre in Schönefeld and pointed out the importance of regional companies for the entire state of Brandenburg. In several rounds, they prevailed against a total of 82 applicants.

Pentracor GmbH with good third quarter 2021 and sales of 0.32 million euros - Pandemic continues to influence development

Hennigsdorf, 27.10.2021 - With 0.32 million euros, the Brandenburg-based medical technology company Pentracor (convertible bond ISIN: DE000A289XB9, WKN: A289XB) achieved a new record in sales in its still young history in the third quarter of 2021. As expected, half-year sales amounted to EUR 0.57 million. In the first nine months of 2021, Pentracor GmbH recorded significantly higher sales revenue of around EUR 0.89 million than in the full year 2020 (EUR 0.35 million).

Therapeutic Success with novel blood washing therapy - Interview with Dr. Ahmed Sheriff

Hennigsdorf, August 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin, publishes an interview with CEO Dr. Ahmed Sheriff.

The innovative and cutting-edge therapy CRP apheresis convinces.

Avoiding serious tissue damage in myocardial infarction and preserving cardiac output. A clinical study on CRP apheresis after myocardial infarction showed significantly positive results. Other cases in clinical practice support these results. Similarly, 9 Covid-19 patients - one before and the others in intensive care - have recovered. The majority were already on artificial ventilation. Unfortunately, about 50 percent of these patients die under normal conditions when treated according to guidelines.

Pentracor GmbH publishes 2020 financial statements and makes good progress in the first half of 2021

Hennigsdorf, July 28, 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin has published its 2020 annual financial statements. The financial year was characterized by the roll-out of the PentraSorb® CRP medical product developed and certified by the company, as well as the initiation and execution of clinical studies to increase acceptance for CRP apheresis in the treatment of diseases associated with acute inflammation such as myocardial infarction.